ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Our lead candidate, BPZE1, is Phase 3 ready and the most advanced next generation pertussis vaccine, having completed four Phase 2 clinical trials.
While BPZE1 is currently an investigational vaccine, the FDA has granted BPZE1 Fast Track designation for active booster immunization against pertussis.
ILiAD Biotechnologies, Inc. is a registered Delaware company founded in 2012.
